In addition, levothyroxine had no significant effect on bone mineral density, fatigue, hypothyroidism symptoms, quality of life, BMI, cognitive function, depression, blood pressure, etc. in older SCH patients, and also did not significantly increase the incidence of adverse events.<h4>Conclusions</h4>Among older SCH patients, levothyroxine treatment may reduce TC, TG, LDL-C, and ApoB. This evidence concerns the gene APOB and spindle cell hemangioma.